ReviewDrugs2016
Sublingual Sufentanil: A Review in Acute Postoperative Pain.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03403842 (Treatment of Acute Post-operative Pain in Patients Undergoing Laparoscopic Colon Resections), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Acute Post-operative Pain in Patients Undergoing Laparoscopic Colon Resections
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- Low-dose sufentanil does not affect tolerance to LBNP-induced central hypovolemia or blood pressure responses during a cold pressor test.American journal of physiology. Regulatory, integrative and comparative physiology · 2024Trial
- Sublingual Administration for Pain Control: Pharmacology, Clinical Applications and Future Directions.CNS drugs · 2026Review
- Sublingual sufentanil after orthopaedic and abdominal surgery: long-term outcome and safety.Perioperative medicine (London, England) · 2025Article
- Sublingual sufentanil for patient-controlled analgesia during labor induction for pregnancy termination: an effective and well-tolerated approach.Journal of anesthesia, analgesia and critical care · 2024Article
- Article
- The Routes of Administration for Acute Postoperative Pain Medication.Pain and therapy · 2021Review
- Genetic Polymorphisms of Cytokines Might Affect Postoperative Sufentanil Dosage for Analgesia in Patients.Journal of pain research · 2020Article
- Formulary Drug Review: Sufentanil Sublingual.Hospital pharmacy · 2019Review
- Sufentanil 30 µg Sublingual Tablet: A Review in Acute Pain.Clinical drug investigation · 2019Review
- Sufentanil Sublingual Tablet System (SSTS) for the management of postoperative pain after major abdominal and gynecological surgery within an ERAS protocol: an observational study.Journal of pain research · 2019Article
- New Advances in Acute Postoperative Pain Management.Current pain and headache reports · 2018Review
- Article
- Special Considerations for the Treatment of Pain from Torture and War.Current anesthesiology reports · 2016Review
- Sufentanil sublingual tablet system (ZalvisoSaudi journal of anaesthesiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sufentanil sublingual tablet system (SSTS; Zalviso(®)) is a novel patient-controlled analgesia (PCA) device intended to overcome some of the drawbacks of opioid-based intravenous PCA (IV-PCA). Based on the results of three phase III studies, the SSTS has been approved in the EU for the management of acute moderate to severe postoperative pain in adults in a hospital setting. In a head-to-head comparison with morphine, the gold standard for opioid-based IV-PCA, the SSTS was associated with a more rapid onset of analgesia and higher rates of success, based on patient and healthcare professional global assessments of the method of pain control. Patients and healthcare professionals also rated the SSTS as being easier to use and expressed a greater level of overall satisfaction with this device. The SSTS was generally well tolerated, with an adverse event profile typical of that of other opioids and generally similar to that of placebo. By virtue of its preprogrammed, noninvasive design, the SSTS avoids the risk of pump programming errors and other complications (e.g. infections and analgesic gaps) that can occur with IV-PCA technology; it also imposes less restriction on postoperative mobility. As such, the SSTS provides an effective alternative to opioid-based IV-PCA for the management of acute moderate to severe postoperative pain. Future studies should ideally focus on evaluating the relative cost effectiveness of the SSTS and comparing it with other available needle-free PCA modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.